An interventional study of Distribution of study questionnaires and tDCS sessions (D1-D10) in Depression, sponsored by Nantes University Hospital. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Nantes University Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in Depression with a site in France — 63 open to participants now, 67 under way, 2 of them phase 3. Depression · France.
Among the 266 studies in Depression with a site in France, this one is the 124th largest by planned enrollment of the 185 interventional ones that give a count, is one of 17 that started in 2026, is one of 133 with no phase, reaches primary completion later than 51 of the 66 other live ones, and was the 258th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →63 of the 266 studies in Depression with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Healthy volunteers
Hospital Ambroise Paré Paris · Sites in France
Ages 18–80
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 7–25
Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI) · Sites in France
Ages 18–42 · Women only
ThIA Santé Mentale · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 30 · Phase 4 9
First in 1990; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 120 across the 185 interventional studies, 158 across the 81 observational. Of the 157 that completed or were terminated, 18 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 266 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 4 studies filed under Depression — fewer than ten, so there is no comparison to draw.
18 of the studies in Depression with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05632757Assistance Publique Hopitaux De MarseilleAnticipated Patient and Caregiver Burden | 2026-12-22 |
| NCT05074901University of BordeauxVirtual Agents-based Digital Interventions to Improve Health | 2026-12-31 |
| NCT06747793University Hospital, ToulouseVirtual Reality to Reduce the Anxiety in Critically Ill Patient | 2027-01 |
| NCT05661383Hôpital le VinatierOlfactory and Brain Stimulations in Treatment-resistant Depression | 2027-01-27 |
| NCT05149742Assistance Publique - Hôpitaux de ParisDeafness and Cognition in Middle-aged Adults | 2027-05-24 |
Add all 18 to your calendar (.ics) → With an account.
Among the 266 studies in Depression with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Transcranial direct current stimulation (tDCS) is a neuromodulation method that modulates brain activity using low-intensity electrical current. Used in the treatment of depression, it is easily adaptable for both caregivers and patients, with good tolerance, under appropriate supervision.
Allowing patients to perform tDCS at home could address issues of access to care (distance from home, overall cost of care, lack of healthcare professionals, difficulty travelling for physical/psychological reasons, etc.). Studies on tDCS have highlighted the importance of regular clinical monitoring to ensure compliance and safety, which are essential factors for therapeutic efficacy.
The main objective of this study is to demonstrate the non-inferiority of tDCS performed at home versus in hospital in terms of effectiveness in reducing depressive symptoms at 6 weeks post-treatment in patients with moderate to severe depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Psychiatric diagnosis:
Drug treatment:
o Failure of a maximum of 1 or 2 antidepressants taken successively or in combination for the current episode
Ability to understand and cooperate:
Exclusion Criteria:
Psychiatric or neurological diagnoses:
History or current treatment of neuromodulation
Medical to stimulation:
Limited ability to participate:
Inability to safely perform tDCS at home, as defined by at least one of the following:
Special legal or social situation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the control group, patients receive tDCS treatment at the hospital under nursing supervision. In the control group, patients receive tDCS treatment at the hospital under nursing supervision.
Other: Distribution of study questionnaires · Other: tDCS sessions (D1-D10) · Other: Semi-structured interviews with patients
As part of the home intervention group, patients undergo a self-administered tDCS treatment, but under remote nursing supervision via the SoomaDuo app (CE marked, used in accordance with the tDCS device). This device allows daily monitoring of treatment, automatic verification of stimulation parameters and complete traceability of compliance.
Other: Distribution of study questionnaires · Other: tDCS sessions (D1-D10) · Other: Monitoring tDCS appropriation · Other: Semi-structured interviews with patients
The questionnaires will be administered to patients at DO, D10, and M2. MADRS/RSES/EQ-5D-5L/BDI/CRQ
Protocol: 2 mA, 30 min, 10 working days (Monday to Friday), 2 sessions/day
During visits to the hospital, the nurse ensures that the patient knows how to use the device correctly.
The interviews will be conducted by telephone with patients participating in the study. The purpose of these interviews is to gather information for the qualitative aspect of the implementation.
Evaluate the non-inferiority of tDCS administered at home compared to in-hospital treatment in terms of effectiveness in reducing depressive symptoms 6 weeks post-treatment, using the MADRS (Montgomery-Asberg Depression Rating Scale).
The scale ranges from 0 to 60, with 60 representing the worst possible outcome.
Time frame: 2 months
Evaluate the response to treatment by comparing the two arms immediately post-treatment and at M2 (6 weeks post-treatment). This will be assessed by the change in the total MADRS scale score.
The scale ranges from 0 to 60, with 60 representing the worst possible outcome.
Time frame: 2 Months
Evaluate the remission rate in each of the two arms immediately after treatment and at M2.
Time frame: 2 months
Compare the change in patient self-reported depressive symptoms using the BDI-II (Beck Depression Inventory-II) in both study arms, measured immediately post-treatment and at M2 (6 weeks post-treatment).
The scale ranges from 0 to 3, where 3 representing the worst possible outcome.
Time frame: 2 months
Assess the impact of tDCS on self-esteem using the Rosenberg Self-Esteem Scale (RSES) in both study arms, measured immediately post-treatment and at M2 (6 weeks post-treatment).
The scale ranges from 1 to 4, where 1 indicates "strongly disagree" and 4 indicates "strongly agree.
Time frame: 2 months
Study patients' quality of life using the EQ-5D-5L after tDCS treatment in each of the two arms immediately after treatment and at M2.
The scale ranges from 0 to 100, with 0 representing the worst possible outcome.
Time frame: 2 months
Assess the safety of the two tDCS administration modalities using the Comfort Rating Questionnaire (CRQ) in each of the two arms immediately after treatment.
The scale ranges from 0 to 10, with 10 representing the worst possible outcome.
Time frame: 10 Days
Compare efficiency from a collective perspective and over a two-month time horizon.
Incremental cost-utility ratio (cost per QALY) at 2 months.
Time frame: 2 months
Analyse the financial impact of the rollout of tDCS at home (budget impact analysis over 5 years)
Time frame: 2 months
Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Relevance
Qualitative analysis of data collected during semi-structured interviews with patients and their relatives regarding the suitability or unsuitability of the method of administering tDCS at home.
Time frame: 2 months
Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Acceptability
* Proportion of reasons for refusal among patients identified but not included following a log-based screening process, linked to a negative perception of tDCS. * Number of patients reporting discomfort during stimulation * Number of patients who withdrew after randomisation due to a negative experience of tDCS.
Time frame: 2 months
Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Fidelity
Ratio of the number of sessions completed to the number of sessions planned in each of the two groups. // Proportion of patients who discontinued the protocol before completion // Factors leading to deviations that resulted in the treatment being carried out over a longer period or in the tDCS stimulation treatment being discontinued.
Time frame: 2 months
Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Adoption
Proportion of individuals included among those identified. Description of the reasons for excluding patients who were identified but not included. Frequency of inclusions.
Time frame: 2 months
Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Implementation Costs (microcosting).
Time frame: 2 months
Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Feasibility
Number of patients who completed the full course of tDCS treatment.
Time frame: 2 months
Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain: Reach (Sociodemographic profile of the patients included)
Time frame: 2 months
Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Sustainability (Integration of the scheme into the facility's care programme)
Time frame: 2 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Mar 2028, 20 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 20 months is close to that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.